A Revolutionary Approach to Cancer Treatment


Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

June 2, 2018
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

May 16, 2018
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

May 9, 2018
Jounce Therapeutics Reports First Quarter 2018 Financial Results

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Cary Pfeffer, M.D.
Partner

Robert Kamen, Ph.D.
Venture Partner